View Item 

Show simple item record

Meta‐analysis: rapid infliximab infusions are safe
dc.contributor.authorNeef, H. C.en_US
dc.contributor.authorRiebschleger, M. P.en_US
dc.contributor.authorAdler, J.en_US
dc.date.accessioned2013-08-02T20:51:48Z
dc.date.available2014-10-06T19:17:44Zen_US
dc.date.issued2013-08en_US
dc.identifier.citationNeef, H. C.; Riebschleger, M. P.; Adler, J. (2013). "Meta‐analysis: rapid infliximab infusions are safe." Alimentary Pharmacology & Therapeutics 38(4): 365-376. <http://hdl.handle.net/2027.42/99086>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/99086
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherJanssen Biotech, Inc.en_US
dc.titleMeta‐analysis: rapid infliximab infusions are safeen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23815183en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/99086/1/apt12389.pdf
dc.identifier.doi10.1111/apt.12389en_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceBhat S, Sharma D, Doherty P, Tham TC, Caddy GR. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010; 16: 1922 – 5.en_US
dc.identifier.citedreferenceBefrits R, Malmström L, Forsell A, Bark L‐Å, Blomquist L. One hour infiximab infusion can replace two hour infusion in maintenance treatment of Crohns disease without shortcomings, in patients treated for up to three years. Gastroenterology 2008; 134: A402.en_US
dc.identifier.citedreferenceBelhassan M, Zeitoun JD, Lefevre JH, et al. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer? Clin Res Hepatol Gastroenterol 2013; 37: 189 – 92.en_US
dc.identifier.citedreferenceEl Miedany Y, Palmer D. Infliximab infusion therapy in inflammatory arthritis: assessment of the accelerated infusion protocol in comparison to the standard infusion approach. Rheumatology (Oxford) 2011; 50: 97 – 97.en_US
dc.identifier.citedreferenceRojany M, Wegelin J, Trudeau W, Prindiville T. A rapid one‐hour infusion of infliximab is well‐tolerated gastroenterology. Gastroenterology 2006; 130: A212.en_US
dc.identifier.citedreferenceSaxena P, Ly C, Leong RW. Accelerated infliximab infusion protocols are safe. Gastroenterology 2011; 140: S276.en_US
dc.identifier.citedreferenceShergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002; 29: 667 – 77.en_US
dc.identifier.citedreferenceBañuelos‐Ramírez D, Ramirez‐Palma MM, Balcazar‐Sanchez ME, Sanchez‐Alonso S. Rapid application of infliximab. Efficacy complications. Reumatol Clin 2007; 3: 171 – 5.en_US
dc.identifier.citedreferenceBreynaert C, Ferrante M, Fidder H, et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single‐center cohort study. Am J Gastroenterol 2011; 106: 778 – 85.en_US
dc.identifier.citedreferenceBuch MH, Bryer D, Lindsay S, Rees‐Evans B, Fairclough A, Emery P. Shortening infusion times for infliximab administration. Rheumatology (Oxford) 2006; 45: 485 – 6.en_US
dc.identifier.citedreferenceClare DF, Alexander FC, Mike S, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009; 21: 71 – 5.en_US
dc.identifier.citedreferenceLee TW, Singh R, Fedorak RN. A one‐hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther 2011; 34: 181 – 7.en_US
dc.identifier.citedreferenceYeckes AR, Hoffenberg EJ. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 49: 151 – 4.en_US
dc.identifier.citedreferenceStroup DF, Berlin JA, Morton SC, et al. Meta‐analysis of observational studies in epidemiology: a proposal for reporting. Meta‐analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008 – 12.en_US
dc.identifier.citedreferenceWells GA, Shea B, O'Connell D, et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta‐analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed March 28, 2013.en_US
dc.identifier.citedreferenceLiberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65 – 94.en_US
dc.identifier.citedreferenceKane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther 2009; 26: 936 – 46.en_US
dc.identifier.citedreferenceCarter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn's disease‐related healthcare utilization and inpatient costs. Adv Ther 2011; 28: 671 – 83.en_US
dc.identifier.citedreferenceFeagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health‐related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794 – 802.en_US
dc.identifier.citedreferenceFeldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double‐blind placebo‐controlled trial. Brit J Dermatol 2005; 152: 954 – 60.en_US
dc.identifier.citedreferenceMaini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932 – 9.en_US
dc.identifier.citedreferenceHanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541 – 9.en_US
dc.identifier.citedreferenceHyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate‐to‐severe Crohn's disease in children. Gastroenterology 2007; 132: 863 – 73.en_US
dc.identifier.citedreferenceAdler J, Sandberg KC, Shpeen BH, et al. Variation in infliximab administration practices in the treatment of pediatric inflammatory bowel disease J Pediatr Gastroenterol Nutr 2013; 57: 35 – 8.en_US
dc.identifier.citedreferenceRemicade (Infliximab) prescribing information [package insert]. Horsham, PA: Janssen Biotech, Inc., 2013.en_US
dc.identifier.citedreferenceOllendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially‐insured setting. Am J Ther 2006; 13: 502 – 6.en_US
dc.identifier.citedreferenceWong BJ, Cifaldi MA, Roy S, Skonieczny DC, Stavrakas S. Analysis of drug and administrative costs allowed by U.S. Private and public third‐party payers for 3 intravenous biologic agents for rheumatoid arthritis. JMCP 2011; 17: 313 – 20.en_US
dc.identifier.citedreferenceVan Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011; 106: 1594 – 602.en_US
dc.identifier.citedreferenceBehm BW, Bickston SJ. Tumor necrosis factor‐alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008; 1: CD006893.en_US
dc.identifier.citedreferenceRutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402 – 13.en_US
dc.identifier.citedreferenceColombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383 – 95.en_US
dc.identifier.citedreferenceJacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11: 442 – 6.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt12389.pdf
Size:
340.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.